Pathology and new insights in thyroid neoplasms in the 2022 WHO classification

被引:10
|
作者
Lebrun, Laetitia [1 ]
Salmon, Isabelle [1 ,2 ,3 ]
机构
[1] Univ Libre Bruxelles ULB, Erasme Univ Hosp, Hop Univ Bruxelles HUB, CUB Hop Erasme,Dept Pathol, Brussels, Belgium
[2] ULB, Ctr Microscopy & Mol Imaging CMMI, DIAPath, Gosselies, Belgium
[3] Univ Libre Bruxelles ULB, Erasme Univ Hosp HUB, Dept Pathol, Rue Meylemeersch 90, B-1070 Brussels, Belgium
关键词
Bethesda system; fine needle aspiration; molecular testing; screening; thyroid cancer; WHO classification; TERT PROMOTER MUTATIONS; ENCAPSULATED FOLLICULAR VARIANT; INTEROBSERVER VARIABILITY; ASSOCIATION GUIDELINES; GENETIC ALTERATIONS; VASCULAR INVASION; TASK-FORCE; CARCINOMA; CANCER; NODULES;
D O I
10.1097/CCO.0000000000001012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of reviewThe assessment of thyroid nodules is a common clinical problem, linked to the high incidence of thyroid nodules in the population and the low incidence of aggressive thyroid carcinoma. The screening is therefore one of the strengths of our patient care. Recently, the 2023 Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) and 2022 WHO classification of thyroid neoplasms have been released based on the definition of new entities and the growing impact of molecular testing. The aim of this review is to analyze how these upgrades can help us in the daily routine practice diagnosis of thyroid cancer.Recent findingsOur review is focused on the most frequent thyroid tumors derived from thyroid follicular cell. Fine needle aspiration (FNA) is the gold standard for the screening of thyroid nodules with very high levels of sensitivity and specificity. These sensitivity and specificity are improved by molecular testing, which refines the risk of malignancy. The 2023 TBSRTC integrates molecular data and the upgrades integrated in the 2022 WHO classification such as the 'low-risk neoplasms' and the 'high-grade follicular-cells derived carcinoma'. The morphological examination remains crucial since the capsular and/or vascular invasion are key features of malignancy in the follicular thyroid neoplasms. Low-risk neoplasms represent a clinical challenge since no specific guidelines are available. Challenges remain regarding oncocytic thyroid lesions, which are not associated with specific diagnostic molecular biomarkers. Molecular testing can help not only in deciphering the prognosis but also in the targeted therapeutic strategy.SummaryWhile molecular testing has succeeded to substantially improve the pre and postoperative diagnosis and risk stratification of thyroid tumors, the morphological examination is still central in the daily routine diagnosis of thyroid pathology. Future is the integrated diagnosis of clinical, morphological, molecular and epigenetic features with the help of artificial intelligence algorithms.
引用
收藏
页码:13 / 21
页数:9
相关论文
共 50 条
  • [21] Sinonasal neoplasms: Update from the WHO 2022
    Agaimy, Abbas
    PATHOLOGIE, 2023, 44 (04): : 233 - 239
  • [22] The Evolving Role of Pathology in New Developments, Classification, Terminology, and Diagnosis of Pancreatobiliary Neoplasms
    Reid, Michelle D.
    Lewis, Melinda M.
    Willingham, Field F.
    Adsay, N. Volkan
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2017, 141 (03) : 366 - 380
  • [23] State-of-the-Art Pathology: New WHO Classification, Implications, and New Developments
    Cunliffe, Clare H.
    Fischer, Ingeborg
    Parag, Yoav
    Fowkes, Mary E.
    NEUROIMAGING CLINICS OF NORTH AMERICA, 2010, 20 (03) : 259 - +
  • [24] Neuroendocrine neoplasms of the gut and pancreas: new insights
    Rindi, Guido
    Wiedenmann, Bertram
    NATURE REVIEWS ENDOCRINOLOGY, 2012, 8 (01) : 54 - 64
  • [25] The new WHO classification and recent results in soft tissue tumor pathology
    Petersen, I.
    PATHOLOGE, 2013, 34 (05): : 436 - 447
  • [26] The new WHO classification and recent results in soft tissue tumor pathology
    Petersen, I.
    PATHOLOGE, 2013, 34 (05): : 436 - 447
  • [27] New information about tumours of the salivary glands WHO classification 2022
    Ihrler, Stephan
    Jurmeister, Philipp
    Haas, Christian
    Greber, Lukas
    Agaimy, Abbas
    PATHOLOGIE, 2023, 44 (04): : 214 - 223
  • [28] New staging classification for pancreatic neuroendocrine neoplasms combining TNM stage and WHO grade classification [1]
    Wang, Min
    Ding, Ding
    Qin, Tingting
    Wang, Hebin
    Liu, Yahui
    Liu, Jianhua
    Liu, Jun
    Zhang, Hang
    Zhao, Junfang
    Wu, Chien-Hui
    Javed, Ammar
    Wolfgang, Christopher
    Guo, Shiwei
    Chen, Qingmin
    Zhao, Weihong
    Shi, Wei
    Zhu, Feng
    Guo, Xingjun
    Li, Xu
    He, Ruizhi
    Xu, Simiao
    Edil, Barish
    Tien, Yu-Wen
    Jin, Gang
    Zheng, Lei
    He, Jin
    Qin, Renyi
    CANCER LETTERS, 2021, 518 : 207 - 213
  • [29] Pathology and Classification of intraductal papillary mucinous Neoplasms of the Pancreas
    Schlitter, A. M.
    Esposito, I.
    CHIRURG, 2012, 83 (02): : 110 - +
  • [30] The new endocrine WHO classification: What does this mean for thyroid cytology?
    Wong, Kristine S.
    Barletta, Justine A.
    CANCER CYTOPATHOLOGY, 2022, 130 (09) : 658 - 662